KIEFER GREENSPAN: Open Payments
NPI 1629573464 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,556 in 106 payments from 20 companies in 2025. Trend: 2023 $5,077 · 2024 $4,708 · 2025 $2,556
Food & beverage: $2,556
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $412 |
| Neurocrine BioSciences, Inc. | 15 | $403 |
| Lundbeck LLC | 10 | $223 |
| E.R. Squibb & Sons, L.L.C. | 9 | $217 |
| Janssen Pharmaceuticals, Inc | 6 | $199 |
| Axsome Therapeutics, Inc. | 7 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $154 |
| Bausch Health US, LLC | 7 | $143 |
| Otsuka America Pharmaceutical, Inc. | 6 | $135 |
| ABBVIE INC. | 5 | $92 |
Products named: INGREZZA, HETLIOZ, REXULTI, COBENFY, SPRAVATO, Auvelity, CAPLYTA, APLENZIN.
Industry payments across CA — which companies pay providers there.
